Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
Ontology highlight
ABSTRACT: This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms,Neoplasms
PROVIDER: 2231198 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA